Radiopharm Theranostics Ltd (ASX:RAD) has appointed Dr Rama Abu Shmeis as senior vice president for Chemistry, Manufacturing and Controls (CMC), to provide creative problem-solving and a big-picture focus on the manufacturing side of the operation.
Dr Shmeis has 23 years of experience in leading strategic, operational and scientific aspects of CMC development and manufacturing across all stages, from pre-clinical through all clinical stages to commercialisation.
She has advanced more than 25 new molecular entities on a speed-to-market timeline, securing global regulatory CMC submissions, approvals and market launches across multiple therapeutic areas including oncology, virology, neuroscience and pain management.
Top shelf experience in US
“We’re obviously thrilled to add another excellent senior team member with top-shelf experience in the USA market,” Radiopharm Theranostics CEO and managing director Riccardo Canevari said.
“Dr Shmeis is known for developing creative solutions to complex problems in the sector, in addition to a strong ability to anticipate risk and therefore establish appropriate strategies to manage this.
“With a big picture focus and high-level attention to detail, we’re looking forward to her contribution to our vision at Radiopharm.”
Most recently Dr Shmeis held the role of vice president, CMC & manufacturing operations at each of B-cell disease-focused TG Therapeutics and immunotherapy developer Checkpoint Therapeutics (NASDAQ:CKPT), serving at these NASDAQ-listed companies for more than five years.
She holds a PhD in Pharmaceutics and a Bachelor of Science in Pharmacy, having been invited to present at national and international conferences, with publications in peer-reviewed journals as well as several patents.